Abstract: The present invention relates to a medicament with an analgesic, antipyretic and/or antiphlogistic action based on a salicylic acid derivative. The prior art has constantly sought alternatives for active components such as acetyl salicylic acid (ASS) and ethenzamide in order to prevent incompatibility, or provide simpler and better, rapidly acting substances in the most varied administration forms. The invention has surprisingly proved that ethenzamide is very rapidly and completely metabolized in the human body to 2-ethoxybenzoic acid. Ethenzamide is only a pro-drug. A metabolization to salicylamide was exluded. It was also possible to prove the analgesic action of 2-ethoxybenzoic acid. It is correlated with the serum levels and is maintained for longer than 8 hours. 2-ethoxybenzoic acid is very rapidly resorbed. The serum maxima were reached after only 30 minutes and 2-ethoxybenzoic acid can still be detected in the serum after 24 hours.

Abstract: The invention relates to a liquid, bismuth containing medicinal product for the oral treatment of gastro-intestinal illnesses such as gastritis, ulcers, etc., caused by campylobacter.The invention provides a closed system, e.g. a single dose container or a multiple dose container with dosing device containing one or more portions of the bismuth containing medicinal product. In addition, a simple, inexpensive production process is proposed, in which the bismuth citrate is suspended in water, slightly heated and, accompanied by the addition of caustic potash solution/aqueous ammonia solution, is dissolved and set to a pH-value between 6.0 and 7.0 Subsequently an aqueous tripotassium citrate-citric acid solution is added and if necessary sterilized. The solution obtained is placed in a multidose container with dosing device, or is initially diluted with water to form a ready to drink solution, portioned into single dose containers and optionally sterilized.